skip to main content

Press Release

Nouveau Biosciences and CanceRx Execute Memorandum of Understanding (MOU) to Advance NBS-002, into Clinical Development. $10 Million Strategic Investment Supports Regulatory and Clinical Advancement of Second Pipeline Asset.

Nouveau Biosciences and CanceRx Execute Memorandum of Understanding (MOU) to Advance NBS-002, into Clinical Development. $10 Million Strategic Investment Supports Regulatory and Clinical Advancement of Second Pipeline Asset.

[New York, NY – February 26, 2026] – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, today announced that it has executed a Memorandum of Understanding (MOU) with CanceRx, a purpose-driven funding and development platform focused on advancing innovative oncology treatments through long-duration capital and strategic partnerships. Under […]

Nouveau Biosciences and University of Virginia (UVA) Announce Second Licensing Agreement to Expand the Company’s Unique Pipeline of Innovative Nanomedicines

Nouveau Biosciences and University of Virginia (UVA) Announce Second Licensing Agreement to Expand the Company’s Unique Pipeline of Innovative Nanomedicines

[New York, NY – February, 10, 2026] – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, today announced that it has executed a second Licensing Agreement with the University of Virginia (UVA) to expand the company’s pipeline. The Licensing Agreement ratifies Nouveau’s rights to six additional novel nanomedicine […]

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies [New York, NY – January 5, 2026] Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has entered into an agreement with Ardena to manufacture […]

Nouveau Biosciences Appoints Joseph Turgeon as Chief Operating Officer

Nouveau Biosciences Appoints Joseph Turgeon as Chief Operating Officer

[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering nanomedicine and targeted oncology therapeutics, today announced the appointment of Joseph Turgeon as Chief Operating Officer. Mr. Turgeon brings more than 38 years of experience in the pharmaceutical and biotechnology industries, with a career distinguished by leadership in oncology drug development, […]

Nouveau Biosciences Appoints Keith M. McGahan as Chief Legal Officer

Nouveau Biosciences Appoints Keith M. McGahan as Chief Legal Officer

[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering next-generation nanomedicine and targeted oncology therapeutics, today announced the appointment of Keith M. McGahan as Chief Legal Officer. Mr. McGahan brings more than two decades of executive leadership experience across the healthcare, pharmaceutical, and life sciences sectors, with a distinguished track […]